Physician profile
David E Harding
NPI 1770662124
$593.41
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $136 · 2021: $22.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $91.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.95 | 2019 | |
| Astellas Pharma US INC | $56.24 | 2019-2020 | |
| Daiichi Sankyo INC. | $55.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.21 | 2019-2020 | |
| Allergan, INC. | $44.83 | 2019-2020 | |
| Amarin Pharma, INC. | $42.82 | 2019 | |
| Novo Nordisk INC | $37.98 | 2019-2020 | |
| Genentech USA, INC. | $29.22 | 2019 | |
| Merck Sharp & Dohme LLC | $27.85 | 2019-2020 | |
| Medtronic, INC. | $22.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.50 | 2019 | |
| Adlon Therapeutics L.P. | $13.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.96 | 2019 | |
| Boston Scientific Corporation | $12.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.